Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2004 2
2005 1
2006 3
2007 6
2008 7
2009 5
2010 9
2011 13
2012 14
2013 13
2014 17
2015 21
2016 23
2017 14
2018 13
2019 19
2020 26
2021 29
2022 29
2023 27
2024 34
2025 25
2026 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

333 results

Results by year

Filters applied: . Clear all
Page 1
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.
Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z, Sun T, Teng Y, Wu X, Ouyang Q, Yan X, Cheng J, Liu Q, Feng J, Wang X, Yin Y, Shi Y, Pan Y, Wang Y, Xie W, Yan M, Liu Y, Yan P, Wu F, Zhu X, Zou J; DAWNA-1 Study Consortium. Xu B, et al. Among authors: zhang p. Nat Med. 2021 Nov;27(11):1904-1909. doi: 10.1038/s41591-021-01562-9. Epub 2021 Nov 4. Nat Med. 2021. PMID: 34737452 Clinical Trial.
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Zhang P, Zhang Q, Tong Z, Sun T, Li W, Ouyang Q, Hu X, Cheng Y, Yan M, Pan Y, Teng Y, Yan X, Wang Y, Xie W, Zeng X, Wang X, Hu C, Geng C, Zhang H, Li W, Wu X, Zhong J, Xu J, Shi Y, Wei W, Bayaxi N, Zhu X, Xu B. Zhang P, et al. Lancet Oncol. 2023 Jun;24(6):646-657. doi: 10.1016/S1470-2045(23)00172-9. Epub 2023 May 11. Lancet Oncol. 2023. PMID: 37182538 Clinical Trial.
Current Development of Glioblastoma Therapeutic Agents.
Wang Z, Peet NP, Zhang P, Jiang Y, Rong L. Wang Z, et al. Among authors: zhang p. Mol Cancer Ther. 2021 Sep;20(9):1521-1532. doi: 10.1158/1535-7163.MCT-21-0159. Epub 2021 Jun 25. Mol Cancer Ther. 2021. PMID: 34172531 Review.
Histological response and hepatic steatosis changes in nonalcoholic fatty liver disease after bariatric surgery: results from the Base-NAFLD Cohort.
Li M, Zeng N, Yang L, Liu Y, Bai R, Zhang N, Song J, Zhang P, Hua R, Cao D, Jin H, Shi X, Bian S, Tian P, Sun G, Yang Z, Zhao X, Zhang D, Zhang P, Zhang Z. Li M, et al. Among authors: zhang p. Int J Surg. 2025 Nov 1;111(11):8037-8049. doi: 10.1097/JS9.0000000000003031. Epub 2025 Jul 28. Int J Surg. 2025. PMID: 40844300 Free PMC article.
Pathological complete response and survival outcomes in single hormone receptor-positive/HER2-negative breast cancer after neoadjuvant chemotherapy and its intrinsic biological features and immune landscape.
Ji L, Chen X, Lyu H, Song G, Xiao M, Li Q, Wang J, Fan Y, Luo Y, Li Q, Chen S, Ma F, Xu B, Zhang P. Ji L, et al. Among authors: zhang p. Breast Cancer Res Treat. 2025 Dec;214(3):367-386. doi: 10.1007/s10549-025-07822-3. Epub 2025 Sep 17. Breast Cancer Res Treat. 2025. PMID: 40963050
Associations between dynamic hematological indicators and outcomes in HR-positive, HER2-negative metastatic breast cancer treated with bireociclib or placebo plus fulvestrant: Findings from the BRIGHT-2 trial.
Xu H, Wang Y, Sa Q, Zhou Y, Ma F, Zhang P, Fan Y, Cai R, Li Q, Lan B, Wang J, Cui L, Tan X, Bai J, Hu Y, Duan X, Yang F, Wang J, Xu B. Xu H, et al. Among authors: zhang p. Breast. 2025 Dec;84:104598. doi: 10.1016/j.breast.2025.104598. Epub 2025 Oct 12. Breast. 2025. PMID: 41175808 Free PMC article. Clinical Trial.
333 results